key: cord-0952720-tc13e4i5
authors: Ruano-Zaragoza, Maria; Carpio-Escalona, Laura V.; Diaz-Beya, Marina; Piris-Villaespesa, Miguel; Castaño-Diez, Sandra; Muñoz-Cano, Rosa; González-de-Olano, David
title: Safety of COVID-19 vaccination in patients with clonal mast cell disorders
date: 2022-02-01
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2022.01.030
sha: bfa261ab469140ca82c05a875ac8a5c84f937b05
doc_id: 952720
cord_uid: tc13e4i5

nan

Allergy Section. Hospital Clinic. Barcelona to other underlying diseases), idiopathic and primary. This latter may be also divided in: 57 One hundred nineteen patients were included. Forty-nine (41.2%) had atopy background 105 and twenty-seven (22.7%) had history of anaphylaxis (see Table 1 premedicated (see Table 1 and Table E1 ). All the ARs occurred within the first 48 hours, 120 but none in the first hour after the administration of the vaccine. We observed a 121 comparable rate of AR to COVID-19 vaccine in our patients compared to the data 122 

Mast cell activation syndromes

Risk and management of patients with mastocytosis and MCAS in the SARS

CoV-2 (COVID-19) pandemic: Expert opinions

Delving Into COVID-19 Vaccination-Induced 145

Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?

COVID-19 Vaccination in Mastocytosis: Recommendations of the European

Cell Diseases (AIM)

mRNA COVID-19 vaccine is well tolerated in 152 patients with cutaneous and systemic mastocytosis with mast cell activation 153 symptoms and anaphylaxis

Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast 156 cell disorders